International Stem Cell (ISCO)
OTHER OTC:ISCO
Top Page
International Stem Cell
(OTC:ISCO)
Select Model
Select Model
Rating:49Neutral
Price Target:
$0.16
▲(32.50% Upside)
Action:ReiteratedDate:03/31/26
The score is held back mainly by weak financial performance—persistent losses, deteriorating recent free cash flow, and a higher-risk balance sheet with periods of negative equity. Technicals are modestly supportive with the price above major moving averages, and valuation appears favorable on a low P/E, but these are not enough to offset the fundamental risk profile.
Positive Factors
Gross margin sustainability
Consistently high gross margins indicate the company’s products/services have durable unit economics. That margin buffer supports gross profitability even with volatile revenue, giving management room to invest in R&D or sales while pursuing a path to operating leverage if top-line stabilizes.
Negative Factors
Weak balance sheet
Repeated periods of negative equity and materially fluctuating debt create financial fragility. That weak capitalization reduces flexibility to fund R&D or scale, raises refinancing and covenant risk, and can deter large partners or investors for longer-term projects.
Read all positive and negative factors
Positive Factors
Negative Factors
Gross margin sustainability
Consistently high gross margins indicate the company’s products/services have durable unit economics. That margin buffer supports gross profitability even with volatile revenue, giving management room to invest in R&D or sales while pursuing a path to operating leverage if top-line stabilizes.
Read all positive factors
International Stem Cell (ISCO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.08M
Dividend YieldN/A
Average Volume (3M)2.04K
Price to Earnings (P/E)―
Beta (1Y)0.09
Revenue Growth10.12%
EPS Growth79.74%
CountryUS
Employees32
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.03
Shares Outstanding8,004,389
10 Day Avg. Volume3,590
30 Day Avg. Volume2,041
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)-0.28
Price to Sales (P/S)0.12
P/FCF Ratio-32.02
Enterprise Value/Market Cap3.57
Enterprise Value/Revenue0.42
Enterprise Value/Gross Profit0.76
Enterprise Value/Ebitda-14.46
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
International Stem Cell Business Overview & Revenue Model
Company Description
International Stem Cell Corporation, a clinical stage biotechnology company, focuses on the development of therapeutic and biomedical products in North America, Asia, Europe, and internationally. The company's products are based on human parthenog...
How the Company Makes Money
ISCO has historically generated revenue through multiple sources tied to its stem cell platforms: (1) sales of stem cell–related products and services (e.g., cell lines, cell-based materials, and/or contract services supporting research and develo...
International Stem Cell Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
22
Negative
Cash Flow
28
Negative
| Breakdown | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 9.10M | 9.09M | 7.79M | 8.18M | 7.18M |
| Gross Profit | 5.07M | 5.32M | 4.61M | 4.91M | 4.24M |
| EBITDA | -48.00K | 142.00K | 202.00K | 22.00K | -220.00K |
| Net Income | -418.00K | -209.00K | -131.00K | -466.00K | -1.04M |
Balance Sheet | |||||
| Total Assets | 4.82M | 5.17M | 5.39M | 5.13M | 4.95M |
| Cash, Cash Equivalents and Short-Term Investments | 993.00K | 1.23M | 1.59M | 742.00K | 171.00K |
| Total Debt | 3.73M | 3.84M | 4.18M | 4.28M | 4.07M |
| Total Liabilities | 4.58M | 9.10M | 5.28M | 9.65M | 9.53M |
| Stockholders Equity | 240.00K | -3.93M | 113.00K | -4.52M | -4.59M |
Cash Flow | |||||
| Free Cash Flow | -35.00K | -153.00K | 846.00K | 321.00K | -1.34M |
| Operating Cash Flow | 8.00K | 13.00K | 929.00K | 332.00K | -1.30M |
| Investing Cash Flow | -45.00K | -171.00K | -83.00K | -11.00K | -45.00K |
| Financing Cash Flow | -200.00K | -200.00K | 0.00 | 250.00K | 824.00K |
International Stem Cell Technical Analysis
Negative
0.12
Price Trends
0.16
Negative
0.15
Negative
0.15
Negative
Market Momentum
<0.01
Positive
41.92
Neutral
42.86
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ISCO, the sentiment is Negative. The current price of 0.12 is below the 20-day moving average (MA) of 0.16, below the 50-day MA of 0.16, and below the 200-day MA of 0.15, indicating a bearish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 41.92 is Neutral, neither overbought nor oversold. The STOCH value of 42.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ISCO.
International Stem Cell Risk Analysis
International Stem Cell disclosed 47 risk factors in its most recent earnings report. International Stem Cell reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
International Stem Cell Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $1.08M | -2.68 | 3.33% | ― | 10.12% | 79.74% | |
44 Neutral | $2.01M | ― | ― | ― | 178.82% | -4121.10% | |
43 Neutral | $1.59M | -0.07 | -63.03% | ― | -100.00% | 86.75% | |
| ― | $2.60M | -0.17 | -168.95% | ― | ― | 90.27% |
* Healthcare Sector Average
ISCO
International Stem Cell
0.14
0.02
12.50%
BDRX
Biodexa Pharmaceuticals
3.51
-71.99
-95.35%
QCLS
Q/C Technologies
3.61
-21.54
-85.65%
SCNI
Scinai Immunotherapeutics
0.58
-1.67
-74.22%
OGEN
Oragenics
0.60
-5.10
-89.49%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.